Yerem Yeghiazarians, MD

Professor

CLINICAL INTERESTS: Dr. Yerem Yeghiazarians is an interventional cardiologist with expertise in managing patients with coronary artery disease, acute coronary syndromes, valvular heart disease, cardiomyopathies, patent foramen ovale, and peripheral arterial diseases. Yeghiazarians earned an undergraduate degree from Brandeis University and a medical degree from the Johns Hopkins School of Medicine. He trained in internal medicine at Brigham and Women's Hospital, Harvard Medical School, where he served as chief medical resident and instructor in medicine. He also completed general and interventional adult cardiology training at the Brigham and Women's Hospital. He has been at UCSF since 2003.

RESEARCH INTERESTS: Dr. Yeghiazarians is the Director of the Translational Cardiac Stem Cell Porgram at UCSF. His research interests are to study the role of stem cells in improving the cardiac function after a myocardial infarction.
Education
M.D., 1995 - School of Medicine, Johns Hopkins University
Websites
Publications
  1. Premature coronary disease, in-stent restenosis and vascular complications in a young man with Behçet syndrome.
  2. Administration of Interleukin-15 peptide improves cardiac function in a mouse model of myocardial infarction.
  3. Echocardiographic determination of pulmonary arterial capacitance.
  4. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy.
  5. TGF-ß1/CD105 signaling controls vascular network formation within growth factor sequestering hyaluronic acid hydrogels.
  6. Aging is protective against pressure overload cardiomyopathy via adaptive extracellular matrix remodeling.
  7. Three-Dimensional Bioprinting: Emerging Technology in Cardiovascular Medicine.
  8. Ferumoxytol MRA for transcatheter aortic valve replacement planning with renal insufficiency.
  9. Matrix metalloproteinase-13 mediated degradation of hyaluronic acid-based matrices orchestrates stem cell engraftment through vascular integration.
  10. Overexpression of Nitric Oxide Synthase Restores Circulating Angiogenic Cell Function in Patients With Coronary Artery Disease: Implications for Autologous Cell Therapy for Myocardial Infarction.
  11. Measurement of absolute myocardial blood flow in humans using dynamic cardiac SPECT and 99mTc-tetrofosmin: Method and validation.
  12. Cardiac stem cell therapy: Have we put too much hype in which cell type to use?
  13. Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction.
  14. A Novel Method for Quantifying Smooth Regional Variations in Myocardial Contractility Within an Infarcted Human Left Ventricle Based on Delay-Enhanced Magnetic Resonance Imaging.
  15. Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate.
  16. HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth.
  17. Enhanced survival and engraftment of transplanted stem cells using growth factor sequestering hydrogels.
  18. Cardiac steatosis potentiates angiotensin II effects in the heart.
  19. Quantitative Signature of Coronary Steal in a Patient with Occluded Coronary Arteries Supported by Collateral Circulation Using Dynamic SPECT.
  20. Trans-radial versus trans-femoral access in patients with end-stage liver disease undergoing cardiac catheterization.
  21. High femoral artery bifurcation predicts contralateral high bifurcation: implications for complex percutaneous cardiovascular procedures requiring large caliber and/or dual access.
  22. Patient and physician perspectives on outcomes weighting in revascularization. The POWR study.
  23. Coronary artery aneurysms in acute coronary syndrome: case series, review, and proposed management strategy.
  24. IL-15: a novel prosurvival signaling pathway in cardiomyocytes.
  25. Cardiac stem cell therapy: review of the native cardiac progenitor cells and future direction.
  26. The effects of aging on apoptosis following myocardial infarction.
  27. Dietary flavanol intervention lowers the levels of endothelial microparticles in coronary artery disease patients.
  28. The effects of intra-arterial vasodilators on radial artery size and spasm: implications for contemporary use of trans-radial access for coronary angiography and percutaneous coronary intervention.
  29. Aging Impairs the Proliferative Capacity of Cardiospheres, Cardiac Progenitor Cells and Cardiac Fibroblasts: Implications for Cell Therapy.
  30. Nuclear localization of the mitochondrial factor HIGD1A during metabolic stress.
  31. Topical nitroglycerin and lidocaine to dilate the radial artery prior to transradial cardiac catheterization: a randomized, placebo-controlled, double-blind clinical trial: the PRE-DILATE Study.
  32. Cellular microparticles in the pathogenesis of pulmonary hypertension.
  33. CD45-positive cells are not an essential component in cardiosphere formation.
  34. Topical nitroglycerin and lidocaine locally vasodilate the radial artery without affecting systemic blood pressure: a dose-finding phase I study.
  35. Injection of human bone marrow and mononuclear cell extract into infarcted mouse hearts results in functional improvement.
  36. Fractionation of mouse bone-marrow cells limits functional efficacy in non-reperfused mouse model of acute myocardial infarction.
  37. Sca-1+ cardiosphere-derived cells are enriched for Isl1-expressing cardiac precursors and improve cardiac function after myocardial injury.
  38. Advanced Donor Age Impairs Bone Marrow Cell Therapeutic Efficacy for Cardiac Disease.
  39. Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition.
  40. Higher fasting glucose levels are associated with reduced circulating angiogenic cell migratory capacity among healthy individuals.
  41. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy.
  42. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.
  43. Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man.
  44. Evidence of diminished coronary flow in pulmonary hypertension: explaining angina pectoris in this patient group?
  45. Post myocardial infarction cardiogenic shock: a review of current therapies.
  46. Atherosclerotic renal artery stenosis--diagnosis and treatment.
  47. Treatment of pulmonary arterial hypertension with circulating angiogenic cells.
  48. Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy.
  49. A murine model of isolated cardiac steatosis leads to cardiomyopathy.
  50. Closure of a para-valvular aortic leak: with the use of 2 AMPLATZER devices and real-time 2- and 3-dimensional transesophageal echocardiography.
  51. Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction.
  52. Subclavian artery stenosis: a review for the vascular medicine practitioner.
  53. Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.
  54. Sterile radial artery granuloma after transradial procedures: a unique and avoidable complication.
  55. Sterile radial artery granuloma after transradial cardiac catheterization.
  56. Arteriotomy closure devices for cardiovascular procedures: a scientific statement from the American Heart Association.
  57. Timed inhibition of p38MAPK directs accelerated differentiation of human embryonic stem cells into cardiomyocytes.
  58. Nitric oxide synthase expression and functional response to nitric oxide are both important modulators of circulating angiogenic cell response to angiogenic stimuli.
  59. Timing of bone marrow cell therapy is more important than repeated injections after myocardial infarction.
  60. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease.
  61. Granulocyte colony stimulating factor in myocardial infarction with low ejection fraction.
  62. Cytokine combination therapy with long-acting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction.
  63. Prolonged therapy with erythropoietin is safe and prevents deterioration of left ventricular systolic function in a porcine model of myocardial infarction.
  64. A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model.
  65. Cardiac CT and percutaneous mitral annuloplasty: a vision of the future?
  66. Left ventricular rupture due to HIV-associated T-cell lymphoma.
  67. Making a smooth vascular exit--does your kidney function matter?
  68. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients.
  69. Roles of matrix metalloproteinases in flow-induced outward vascular remodeling.
  70. Left ventricular remodeling after myocardial infarction: characterization of a swine model on beta-blocker therapy.
  71. Patent foramen ovale and atrial septal aneurysm: achieving closure.
  72. Pre-PCI white blood cell count: should we care?
  73. Rotational vs. standard coronary angiography: an image content analysis.
  74. Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy.
  75. Peripheral arterial function in infants and young children with one-ventricle physiology and hypoxemia.
  76. Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation.
  77. Magnesium sulfate for transradial cardiac catheterization: teaching an old dog new tricks.
  78. Impaired endothelial progenitor cell function predicts age-dependent carotid intimal thickening.
  79. Another kind of broken heart.
  80. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production.
  81. Pleiotrophin induces nitric oxide dependent migration of endothelial progenitor cells.
  82. Stent thrombosis--a complication best avoided.
  83. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension.
  84. AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmid.
  85. In vivo measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound.
  86. DES for SVG stenosis -- we all want to do it, but are we there yet?
  87. Secrets of success in unprotected left main intervention: patient and lesion selection.
  88. Is it time to burst the "balloon" for high-risk patients?
  89. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro.
  90. Improved characterization of atherosclerotic plaques by gadolinium contrast during intravascular magnetic resonance imaging of human arteries.
  91. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches.
  92. Regions of low endothelial shear stress are the sites where coronary plaque progresses and vascular remodelling occurs in humans: an in vivo serial study.
  93. Determination of adequate coronary stent expansion using StentBoost, a novel fluoroscopic image processing technique.
  94. Validation of the wall motion score and myocardial performance indexes as novel techniques to assess cardiac function in mice after myocardial infarction.
  95. Anomalous origin of the left coronary artery from the pulmonary artery: a case series and brief review.
  96. Phonocardiographic timing of third and fourth heart sounds during acute myocardial infarction.
  97. Remodeling characteristics of minimally diseased coronary arteries are consistent along the length of the artery.
  98. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging.
  99. Randomized study of the safety and clinical utility of rotational vs. standard coronary angiography using a flat-panel detector.
  100. Closed-chest cell injections into mouse myocardium guided by high-resolution echocardiography.
  101. Prediction of sites of coronary atherosclerosis progression: In vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior.
  102. Reproducibility of coronary lumen, plaque, and vessel wall reconstruction and of endothelial shear stress measurements in vivo in humans.
  103. Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study.
  104. Early glycoprotein IIb/IIIa inhibitors in patients with non-ST-segment elevation myocardial infarction: are we ready to open the floodgates?
  105. ST-Segment Elevation Myocardial Infarction.
  106. Unstable angina pectoris.
  107. Efficient reactivation of Xenopus erythrocyte nuclei in Xenopus egg extracts.